HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

11/18/21 6:16:16 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELOX

Date	Price Target	Rating	Analyst
12/17/2021	$4.00	Outperform	Oppenheimer
11/18/2021	$2.00 → $1.00	Neutral	HC Wainwright & Co.
11/11/2021	$3.00 → $2.00	Neutral	HC Wainwright & Co.
6/30/2021	$3.10	Buy	Mizuho